UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2022

Commission File Number 000-54949

BioAdaptives Inc.
(Exact name of registrant as specified in its charter)
Delaware	46-2592228
---	---
(State or other jurisdiction of<br><br>incorporation or organization)	(IRS Employer<br><br>Identification No.)
2620 Regatta Drive, Suite 102, Las Vegas, NV	89128
(Address of principal executive offices)	(Zip Code)

(702) 659-8829

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ Yes ☐ NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non- accelerated filer, or a small reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☐	Smaller reporting Company	☒
Emerging Growth Company	☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ☐ YES ☒ NO

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

103,813,455 common shares issued and outstanding as of August 10, 2022.

Form 10-Q

PART I – FINANCIAL INFORMATION
Item 1.	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of operations	15
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	21
Item 4.	Controls and Procedures	21
PART II – OTHER INFORMATION
Item 1.	Legal Proceedings	23
Item 1A.	Risk Factors	23
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 3.	Defaults Upon Senior Securities	25
Item 4.	Mine Safety Disclosure	25
Item 5.	Other Information	25
Item 6.	Exhibits	25
	Signatures	26
2
---
Table of Contents

CONSOLIDATED BALANCE SHEETS

(Unaudited)

			December 31,
			2021
ASSETS
Current Assets:
Cash	49,517		$	82,936
Prepaid expense	1,000			1,000
Marketable securities	63			190
Inventory	10,647			4,750
Total Current Assets	61,227			88,876
License and patent, net	8,150			59,709
TOTAL ASSETS	69,377		$	148,585
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities:
Accounts payable and accrued liabilities	391,399			247,750
Derivative liabilities	722,664			557,042
Current portion of convertible notes - net of discount of 34,786 and 13,333	440,014			403,117
Note payable - related party	10,246			33,715
Total Current Liabilities	1,564,323			1,241,624
Total Liabilities	1,564,323			1,241,624
Stockholders' Deficit:
Preferred stock, (0.0001 par value, 10,000,000 shares authorized;
Series A Preferred Stock 4,000,000 shares designated; 1,600,000 issued and outstanding, respectively	160			160
Series B Preferred Stock 6,000,000 shares designated; no share issued and outstanding	-			-
Common stock (0.0001 par value, 750,000,000 shares authorized; 77,457,483 and 50,819,780 shares issued and outstanding, and 10,000 issuable, respectively)	7,746			5,082
Additional paid-in capital	5,744,225			5,557,828
Accumulated deficit	(7,247,077	)		(6,656,109	)
Total Stockholders' Deficit	(1,494,946	)		(1,093,039	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	69,377		$	148,585

All values are in US Dollars.

The accompanying notes are an integral part of these unaudited consolidated financial statements.

3
Table of Contents

BIOADAPTIVES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	Three Months Ended						Six months ended
	June 30,						June 30,
	2022			2021			2022			2021
Revenues	$	4,322		$	6,065		$	9,855		$	10,583
Cost of revenue		2,169			2,713			5,759			4,735
Gross Profit		2,153			3,352			4,096			5,848
Operating Expenses
General and administrative		87,517			33,690			192,717			42,320
Professional fees		34,112			15,639			71,944			37,622
Stock based compensation		-			-			-			163,900
Amortization of license and patent		23,821			25,625			56,988			47,500
Total Operating Expenses		145,450			74,954			321,649			291,342
Other Income (Expense)
Unrealized gain (loss) on marketable securities		(106	)		(2,517	)		(127	)		317
Interest expense		(75,367	)		(15,833	)		(105,466	)		(77,249	)
Change in fair value of derivative liabilities		(5,067	)		(219,294	)		(167,822	)		(387,723	)
Loss on settlement of debt		-			-			-			(51,000	)
Total Other Expense		(80,540	)		(237,644	)		(273,415	)		(515,655	)
Loss before income taxes		(223,837	)		(309,246	)		(590,968	)		(801,149	)
Net Loss	$	(223,837	)	$	(309,246	)	$	(590,968	)	$	(801,149	)
Net Loss Per Common Share:
Basic and Diluted	$	(0.00	)	$	(0.01	)	$	(0.01	)	$	(0.03	)
Weighted Average Number of Common Shares Outstanding:
Basic and Diluted		67,545,413			33,032,425			60,677,388			30,603,899

The accompanying notes are an integral part of these unaudited consolidated financial statements

4
Table of Contents

BIOADAPTIVES, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT

(UNAUDITED)

For the Three and Six months ended June 30, 2022

	Series A Preferred stock				Common stock				Additional<br><br>paid-in		Accumulated
	Shares		Amount		Shares		Amount		capital		Deficit			Total
Balance, December 31, 2021		1,600,000	$	160		50,819,780	$	5,082	$	5,557,828	$	(6,656,109	)	$	(1,093,039	)
Common stock issued for conversion of debt		-		-		7,540,799		754		51,263		-			52,017
Debts forgiveness - related party		-		-		-		-		10,000		-			10,000
Net loss for the period		-		-		-		-		-		(367,131	)		(367,131	)
Balance, March 31, 2022		1,600,000	$	160		58,360,579	$	5,836	$	5,619,091	$	(7,023,240	)	$	(1,398,153	)
Common stock issued for conversion of debt		-		-		19,096,904		1,910		119,705		-			121,615
Warrant issued for acquisition of patent		-		-		-		-		5,429		-			5,429
Net loss for the period		-		-		-		-		-		(223,837	)		(223,837	)
Balance, June 30, 2022		1,600,000	$	160		77,457,483	$	7,746	$	5,744,225	$	(7,247,077	)	$	(1,494,946	)

For the Three and Six months ended June 30, 2021

											Additional
	Series A Preferred stock				Common stock						paid-in		Accumulated
	Shares		Amount		Shares			Amount			capital		Deficit			Total
Balance, December 31, 2020		-	$	-		21,591,942		$	2,159		$	4,225,217	$	(5,606,161	)	$	(1,378,785	)
Series A preferred stock issued for settlement of debt - related party		600,000		60		-			-			74,940		-			75,000
Series A preferred stock issued for license fee		500,000		50		-			-			102,450		-			102,500
Common stock issued for conversion of debt		-		-		10,792,873			1,079			485,533		-			486,612
Common stock issued for service		-		-		1,000,000			100			163,800		-			163,900
Cancellation of common stock - officers		-		-		(352,390	)		(35	)		35		-			-
Net loss for the period		-		-		-			-			-		(491,903	)		(491,903	)
Balance, March 31, 2021		1,100,000	$	110		33,032,425		$	3,303		$	5,051,975	$	(6,098,064	)	$	(1,042,676	)
Net loss for the period		-		-		-			-			-		(309,246	)		(309,246	)
Balance, June 30, 2021		1,100,000	$	110		33,032,425		$	3,303		$	5,051,975	$	(6,407,310	)	$	(1,351,922	)

The accompanying notes are an integral part of these unaudited consolidated financial statements.

5
Table of Contents

BIOADAPTIVES, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Six Months Ended
	June 30,
	2022			2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(590,968	)	$	(801,149	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		-			163,900
Change in fair value of derivative liabilities		167,822			387,723
Amortization of license and patent		56,988			47,500
Amortization of debt discount		79,547			48,048
Loss on settlement of debt		-			51,000
Unrealized (gain) loss on investments in marketable securities		127			(317	)
Changes in operating assets and liabilities:
Inventory		(5,897	)		3,118
Prepaid expense and other current assets		-			-
Accounts payable and accrued liabilities		157,431			10,103
Due to related party		1,803			-
Net Cash Used in Operating Activities		(133,147	)		(90,074	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceed from related party		1,623			1,623
Repayment to related party		(1,623	)		(1,623	)
Repayment of notes payable - related party		(25,272	)		(10,000	)
Proceeds from convertible notes		125,000			165,000
Net Cash Provided by Financing Activities		99,728			155,000
Net change in cash		(33,419	)		64,926
Cash at beginning of period		82,936			4,587
Cash at end of period	$	49,517		$	69,513
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for income taxes	$	-		$	-
Cash paid for interest	$	4,728		$	16,424
NON-CASH INVESTING AND FINANCING ACTIVITIES
Derivative liability recognized as debt discount	$	92,000		$	40,000
Issuance of common stock for conversion of debt	$	173,632		$	486,612
Issuance Series A preferred stock for license fee	$	-		$	102,500
Issuance Series A preferred stock for settlement of debt - related party	$	-		$	60
Debts forgiveness - related party	$	10,000		$	-
Warrant issued for Patent's acquisition	$	5,429		$	-
Cancellation of common stock	$	-		$	35

The accompanying notes are an integral part of these unaudited consolidated financial statements.

6
Table of Contents

BioAdaptives, Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1. DESCRIPTION OF BUSINESS AND HISTORY

Description of business

BioAdaptives, Inc. (“BioAdaptives” or the ”Company”) was incorporated in Delaware on April 19, 2013, under the name Apex 8, Inc. Shortly afterwards, the Company’s control person sold his interest; new owners appointed management and changed its name to BioAdaptives, Inc. The Company acquired assets relating to the investigation, development and marketing of nutraceutical products; equipment designed to improve the bioavailability of nutrients in humans and animals; and licenses for specific products.

We commenced investigation of the role of various botanicals in primitive cell development and proliferation, including certain algae along with herbs used in Traditional Chinese Medicine and Ayurvedic Practice. In the course of this investigation, BioAdaptives identified several potential human and animal products. The Company terminated further work on the equipment and products licensed in its early stages to concentrate on these products, for both human and animals.

The Company’s current nutraceutical products are natural plant- and algal-based dietary supplements for humans and animals developed with our knowledge of natural foods. Our product lines includes PluriCell®, PluriPain®, and PrimiLung™ for humans along with Equine All-in-One™ and a related Booster for horses.

Our human products are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; provide pain relief and healing; and improve overall emotional and physical wellness. The science behind our products has proven to be effective for performance enhancement and pain relief for horses and dogs as well as providing improvements in appearance and we have developed products to utilize these advances.

The Company also markets the Lung Cleanser™ medical device, which is sold with our PrimiLung® product as part of a Lung Armor™ package. Additionally, during this reporting period, the Company acquired patent rights to a method to embed oxygen in water and is developing commercial products based on this technology that will augment and complement our current product lines.

All of these products are sold under licensing and manufacturing agreements with third-parties and our current activities are reliant on marketing and distributing products developed and owned by others.

In February 2022, the Company acquired US Patent rights to a process that increases dissolved oxygen in water. The process produces MorO2, ingestion of which is believed to increase diffusion of oxygen into muscle tissues. The Company is developing a business plan to manufacture and market products based on the MorO2 technology..

The Company’s corporate office is located at 2620 Regatta Drive, Suite 102, Las Vegas, NV 89128, and it maintains fulfillment facilities at 4385 Cameron Street, Suite B, Las Vegas, NV 89103.

COVID-19

A novel strain of coronavirus (COVID-19) was first identified in December 2019, and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. Additional strains of COVID-19 are currently in circulation, and the CDC has stated that the virus will continue to impact the US population. As a result of the outbreak, many companies have experienced disruptions in their operations and in markets served. The Company has instituted some and may take additional temporary precautionary measures intended to help ensure the well-being of its employees and minimize business disruption. The Company considered the impact of COVID-19 on the assumptions and estimates used and determined that there were no material adverse impacts on the Company’s results of operations and financial position on June 30, 2022. The full extent of the future impacts of COVID-19 on the Company’s operations is uncertain. A prolonged outbreak could have a material adverse impact on financial results and business operations of the Company, including the timing and ability of the Company to collect accounts receivable and the ability of the Company to continue to provide high quality services to its clients. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change, as new events occur, and additional information is obtained.

7
Table of Contents

2. SUMMARY OF SIGNIFICANT POLICIES

Basis of presentation

The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements filed with the SEC on Form 10K. In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for a fair presentation of financial position and the results of operations for the interim period presented, have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10K filed with SEC on March 31, 2022, have been omitted.

Consolidation

The accompanying consolidated financial statements include the accounts of the Company and its 100% owned subsidiaries, Blenders Choice Inc and MORO2, Inc. All inter-company balances and transactions have been eliminated. The Company and its subsidiary will be collectively referred to herein as the “Company.”

Use of estimates

The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.

Earnings (loss) per share

Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued. Diluted earnings per share excludes all dilutive potential shares if their effect is anti-dilutive.

Financial Instruments and Fair Value Measurements

As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement).

The following table summarizes fair value measurements by level on June 30, 2022 and December 31, 2021, measured at fair value on a recurring basis:

8
Table of Contents

Fair Value Measurements as of June 30, 2022, Using:

	Total Carrying Value as of<br><br>June 30,		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	2022		(Level 1)		(Level 2)		(Level 3)
Assets:
Equity Securities	$	63	$	63	$	-	$	-
Liabilities
Derivative liabilities	$	722,664	$	-	$	-	$	722,664

Fair Value Measurements as of December 31, 2021, Using:

	Total Carrying<br><br>Value as of<br><br>December 31,		Quoted Market<br><br>Prices in Active<br><br>Markets		Significant<br><br>Other<br><br>Observable<br><br>Inputs		Significant<br><br>Unobservable<br><br>Inputs
	2021		(Level 1)		(Level 2)		(Level 3)
Assets:
Equity Securities	$	190	$	190	$	-	$	-
Liabilities
Derivative liabilities	$	557,042		-		-		557,042

Intangible Assets

The Company capitalizes certain costs to acquire intangible assets; if such assets are determined to have a finite useful life they are amortized on a straight-line basis over the estimated useful life.

The Company tests its intangible assets for impairment at least annually and whenever events or circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator of impairment has occurred. Such indicators may include, among others and without limitation: a significant decline in the Company’s expected future cash flows; a sustained, significant decline in the Company’s stock price and market capitalization; a significant adverse change in legal factors or in the business climate of the Company’s segments; unanticipated competition; and slower growth rates.

Recent Accounting Pronouncements

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on our financial statements.

3. GOING CONCERN

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and had an accumulated deficit of $7,247,077 as of June 30, 2022. The Company requires capital for its contemplated operational and marketing activities. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

9
Table of Contents

In order to mitigate the risk related with this uncertainty, the Company plans to issue additional shares of common stock for cash and services during the next 12 months.

4. MARKETABLE SECURITIES

Equity securities on June 30, 2022, and December 31, 2021, were comprised of 105,736 shares of common stock of Hemp, Inc. (HEMP.PK) recorded at fair value of $63 and $190, respectively.

5. LICENSE AND PATENT

During the year ended December 31, 2021, the Company entered into three license and royalty agreements for human and animal nutraceutical products, which it currently markets. These agreements are for a period of one year and the Company issued 1,000,000 shares of Series A preferred stock valued at $193,500 in consideration of these licenses. The Company has capitalized the costs associated with licenses.

During the six months ended June 30, 2022, and 2021, the Company recognized $55,917 and $47,500 in amortization expenses of license fees, respectively. As of June 30, 2022, and December 31, 2021, the asset value of the licenses was $3,792 and $59,709, respectively.

On February 2, 2022, the Company entered in a Patent Purchase and Consulting Agreement (“Agreement”) with an individual as inventor of the technology identified in and owns US Patent No. U.S. Patent 9,783,432B (the “Patent”), which covers technology used in enhancing the capability of water to hold significantly larger amounts of oxygen. The Company granted 1,000,000 shares warrant and has capitalized the cost of $5,429 as patent

During the six months ended June 30, 2022, the Company recognized $1,071 in amortization expenses of patent cost. As of June 30, 2022, the asset value of the patent was $4,358.

6. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities on June 30, 2022, and December 31, 2021, consists of the following.

	June 30,		December 31,
	2022		2021
Accounts payable	$	2,503	$	1,750
Accrued salary		300,000		166,666
Accrued interest		87,750		68,341
Accrued liabilities		3,146		10,993
	$	391,399	$	247,750

7. CONVERTIBLE NOTES

Convertible notes on June 30, 2022, and December 31, 2021, consists of the following:

	June 30,		****	December 31,		****
****	2022		****	2021
Convertible Notes - originated in April 2018	$	95,000		$	95,000
Convertible Notes - originated in June 2018		166,000			166,000
Convertible Notes - originated in October 2018		50,000			50,000
Convertible Notes - issued fiscal year 2021		29,800			105,450
Convertible Notes - issued January 2022		134,000			-
Total convertible notes payable		474,800			416,450
Less: Unamortized debt discount		(34,786	)		(13,333	)
Total convertible notes		440,014			403,117
Less: current portion of convertible notes		440,014			403,117
Long-term convertible notes	$	-		$	-
10
---
Table of Contents

For the six months ended June 30, 2022, and 2021, the interest expense on convertible notes was $25,556 and $28,146, respectively. As of June 30, 2022, and December 31, 2021, the accrued interest was $84,873 and $63,100, respectively.

The Company recognized amortization expense related to the debt discount of $79,547 and $48,048 for the six months ended June 30, 2022 and 2021, respectively, which is included in interest expense in the statements of operation.

Conversion

During the six months ended June 30, 2022, the Company converted notes with principal amounts of $75,650 and accrued interest of $3,783 into 26,637,703 shares of common stock. The corresponding derivative liability at the date of conversion of $94,200 was credited to additional paid in capital.

Convertible Notes - Issued during the year ended December 31, 2018

During the year ended December 31, 2018, the Company issued a total principal amount of $426,000 convertible notes for cash proceeds of $426,000. The convertible notes were also provided with a total of 107,000 common shares valued at $22,210. The terms of convertible notes are summarized as follows:

·	Term two years;
·	Annual interest rates 12%;
·	Convertible at the option of the holders at any time
·	Conversion prices are based on 50% discount to market value for the common stock based on a 4-week weekly average of the closing price.

Convertible Notes - Issued during the year ended December 31, 2021

During the year ended December 31, 2021, the Company issued a total principal amount of $277,500 in convertible note for cash proceeds of $257,000. The terms of convertible note are summarized as follows:

·	Term one year;
·	Annual interest rates 10%;
·	Convertible at 180 days from issuance
·	Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date.

During the six months ended June 30, 2022, the Company converted principal of $50,450 and accrued interest of $3,783 into 16,557,703 shares of common stock.

11
Table of Contents

Convertible Notes - Issued during the year ended December 31, 2022

During the six months ended June 30, 2022, the Company issued a total principal amount of $134,000 in convertible notes for cash proceeds of $125,000. The terms of convertible notes are summarized as follows:

·	Term one year;
·	Annual interest rates 10%;
·	Convertible at 180 days from issuance
·	Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date.

The Company valued the conversion feature using the Black-Scholes pricing model. The fair value of the derivative liability for all the notes that became convertible, including the notes issued in prior years, during the six months ended June 30, 2022, amounted to $120,960, and $92,000 of the value assigned to the derivative liability was recognized as a debt discount to the notes while the balance of $28,960 was recognized as a “day 1” derivative loss.

8. DERIVATIVE LIABILITIES

The Company analyzed the conversion option for derivative accounting consideration under ASC 815, Derivatives and Hedging, and hedging, and determined that the instrument should be classified as a liability since the conversion option becomes effective at issuance resulting in there being no explicit limit to the number of shares to be delivered upon settlement of the above conversion options. The Company accounts for warrants as a derivative liability due to there being no explicit limit to the number of shares to be delivered upon settlement of all conversion options.

Fair Value Assumptions Used in Accounting for Derivative Liabilities.

ASC 815 requires we assess the fair market value of derivative liability at the end of each reporting period and recognize any change in the fair market value as other income or expense item.

The Company determined our derivative liabilities to be a Level 3 fair value measurement and used the Black-Scholes pricing model to calculate the fair value as of June 30, 2022. The Black-Scholes model requires six basic data inputs: the exercise or strike price, time to expiration, the risk-free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each convertible note is estimated using the Black-Scholes valuation model.

For the six months ended June 30, 2022, and year ended December 31, 2021, the estimated fair values of the liabilities measured on a recurring basis are as follows:

	Six Months Ended		Year ended
****	June 30,		December 31,
****	2022		2021
Expected term	0.06 - 0.51 years		0.02- 0.51 years
Expected average volatility	72% - 164%		128% - 315%
Expected dividend yield		-		-
Risk-free interest rate	0.17% - 2.56%		0.03% - 0.07%
12
---
Table of Contents

The following table summarizes the changes in the derivative liabilities during the six months ended June 30, 2022.

Fair Value Measurements Using Significant Observable Inputs (Level 3)
Balance - December 31, 2021	$	557,042
Addition of new derivatives recognized as debt discounts		92,000
Addition of new derivatives recognized as loss on derivatives		28,960
Settled on issuance of common stock		(94,200	)
Loss on change in fair value of the derivative		138,862
Balance - June 30, 2022	$	722,664

The aggregate loss on derivatives during the six months ended June 30, 2022, and 2021 was as follows:

	Six Months Ended
****	June 30,
****	2022		2021
Day one loss due to derivative liabilities on convertible notes	$	28,960	$	101,805
Loss on change in fair value of the derivative liabilities		138,862		285,918
	$	167,822	$	387,723

9. STOCKHOLDERS’ EQUITY

Preferred Stock

On January 24, 2022, the Board of Directors of the Company’s, approved for an increase in the number of authorized shares of the Company’s preferred stock from 5,000,000 shares to 10,000,000 shares.

The Company is authorized to issue 10,000,000 shares of $0.001 par value preferred stock, of which 4,000,000 have been designated as Series A Preferred Stock and 6,000,000 have been designated as Series B Preferred Stock.

Series A Preferred Stock

On February 6, 2020, the Company established its Series A Preferred Stock, par value 0.0001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company’s board exercised “blank check” authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 4,000,000 shares of Series A Preferred Stock.

The Company may use the Series A Preferred Stock for purpose of asset acquisition or in satisfaction of recognized debt; they are not otherwise available for sale. The Series A Preferred Stock have enhanced voting privileges under certain circumstances; the collective right to appoint elect one director, at the Holders’ option; and conversion-to-common rights at a 5:1 ratio.

There are 1,600,000 shares of Series A shares issued as of the date of this filing.

Series B Preferred Stock

Effective January 26, 2022, the Company established its Series B Preferred Stock, par value 0.0001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company’s board exercised “blank check” authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 6,000,000 shares of Series B Preferred Stock.

The Company may use the Series B Preferred Stock for purpose of asset acquisition or other financing purposes. The Series B Preferred Stock have enhanced (100:1) voting privileges; the collective right to appoint elect one director, at the Holders’ option; and conversion-to-common rights at a 10:1 ratio.

There are no Series B shares issued as of the date of this filing.

13
Table of Contents

Common Stock

On January 24, 2022, the holders of a majority of the Company’s outstanding voting stock, approved for an increase in the number of authorized shares of the Company’s common stock from 200,000,000 shares to 750,000,000 shares.

During the six months ended June 30, 2022, the Company issued 26,637,703 shares of common stock valued at $173,632 for conversion of debt.

As of June 30, 2022, and December 31, 2021, there were 77,457,483 and 50,809,780 shares of the Company’s common stock issued and outstanding, respectively.

Warrant

On February 6, 2022, in conjunction with purchase of patent, the Company granted 1,000,000 shares for period of two years with exercise price of $0.006 per share. The fair value of granted shares at issuance date was $5,429. The Company recorded warrant as additional paid-in-capital.

For the six months ended June 30, 2022, the estimated fair values of the warrant measured on a recurring basis are as follows:

	Six Months Ended		****
****	June 30,		****
****	2022
Expected term	2.00 years
Expected average volatility		235	%
Expected dividend yield		-
Risk-free interest rate		1.31	%

10. RELATED PARTY TRANSACTIONS

Notes payable - related party

During the six months ended June 30, 2022, and 2021, the Company repaid notes payable of $25,272 and $10,000 and accrued interest of $4,728 and $0 to a related party, respectively. During the six months ended June 30, 2022 and 2021, the Company recognized interest of $363 and $1,055, respectively.

As of June 30, 2022, and December 31, 2021, the Company recorded notes payable - related party of $8,443 and $33,715 and accrued interest of $876 and $5,241, respectively. The note is a 4% interest bearing promissory note that the term is 1 year.

Due to related party

During the six months ended June 30, 2022, Dr. Edward E. Jacobs, M.D., our CEO, advanced $2,346 for operating expenses and $543 was reimbursed. As of June 30, 2022, due to related party of $1,803.

Employee agreements

On January 1, 2022, the Company entered into a Restricted Stock Unit Termination Agreement for modification of employment agreements signed during 2021 with Dr. Edward E. Jacobs, M.D, Charles Townsend and Robert Ellis. The employees agreed to waive all rights under previously issued RSUs as of January 1, 2022 in exchange for one -time issuance 100,000 shares of restricted common stock. In addition, the Employment Agreement was modified to provide for compensation in the form of a number of Warrants, equivalent to twice (2X) the number of shares previously payable in RSUs and the exercise price of the Warrant shall be the OTC Market price of the Company’s common shares.

During the six months ended June 30, 2022, the Company accrued salary of $133,334.

Debt forgiveness

During the six months ended June 30, 2022, the Company recognized $10,000 accrued salary payable to Robert Ellis related to year 2020 as additional paid-in -capital, based on released agreement in year 2020 due to COVID-19-based financial and other considerations.

12. SUBSEQUENT EVENTS

Management has evaluated subsequent events through the date these financial statements were available to be issued. Based on our evaluation no material events have occurred that require disclosure.

14
Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

FORWARD LOOKING STATEMENTS

This current report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward- looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our unaudited financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.

Our financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles.

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to “common shares” refer to the common shares in our capital stock.

As used in this quarterly report, the terms “we”, “us”, “our”, “Company” and "BioAdaptives" mean BioAdaptives Inc., unless otherwise indicated.

1. OUR BUSINESS

Overview

BioAdaptives’ core business is to investigate, market and distribute natural plant- and algal-based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties.

Effective November 15, 2021, the Company entered into a marketing agreement for an FDA-cleared Class II medical device, the Lung Flute™. The Company is also exploring agreements with other medical device manufacturers; the owners of intellectual property relating to medical devices and processes; and marketing companies associated with these manufacturers and owners.

The Company’s current products include dietary supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients in foods and beverages. The human products are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; provide pain relief and healing; and improve overall emotional and physical wellness. The science behind our human products has proven to be effective for performance enhancement and pain relief for horses and dogs as well as providing improvements in appearance.

15
Table of Contents

Our current product line for humans includes PluriPain®, PrimiLungs™, PrimiSleep™ and recently introduced MindnMemory™, which is an improvement on the discontinued PrimiLive® product. We also market the Lung Flute™ and PrimiLungs™ product in our Lung Armor™ packaging, emphasizing the anti-viral properties of the nutraceutical and general respiratory health benefits from use of the device. MindnMemory™ is a nootropic formulation designed to enhance mental clarity and memory; PrimiSleep™ is a natural soporific that aids relaxation and sleep quality. We acquired the PrimiSleep™ license in 2021, and the revised formulation for MindnMemory™ during 2022, and have commenced marketing activities for these products. Sales of the LungFlute™ have not met our expectations and we anticipate discontinuing marketing this product to concentrate our efforts on our pain, sleep and nootropic human products.

Our animal products include an Equine All-in-One™ formulation, which we market to trainers, horse owners and boarding stables, and a Canine All-in-One™ that we market directly to consumers. Anecdotal and testimonial reports are that the equine products provide significant relief from exercise induced pulmonary hemorrhaging, as well as improved coat and mane appearance and hoof health. The canine products have demonstrated significant rejuvenating benefits for older dogs, improving overall appearance and energy levels.

Effective February 2, 2022, the Company acquired the exclusive option to purchase U.S. Patent No. 9,783,432B (the “Patent”), covering technology used in enhancing the capability of water to hold significantly larger amounts of oxygen. The Agreement also allows the Company a two-year license to use the technology covered by the Patent, including for further development of oxygenated water products for consumers. The Agreement is more fully discussed in the Company’s Form 8-K filed on February 6, 2022. The Company intends to develop consumer products using the oxygenation technology, and has formed a wholly-owned subsidiary, MORO2, Inc. to conduct these activities.

On June 6, 2022, we entered into a services agreement with Wildpack Beverages in Las Vegas, Nevada to co-pack a pilot run (1333 cases) of MorO2. Technical problems prevented completion of the pilot run and we are working with Wildpack to rectify these issues. We will use the pilot run production for testing and promotional purposes and do not expect to generate revenues from sales of MorO2 and related products until 4Q at the earliest.

While we continue to investigate and acquire nutraceutical products for humans and animals, all of our current activities are reliant on marketing and distributing products developed and owned by others. We do not own the formulations for our key products and manufacture and market them under an agreement with the developer that requires payment of a royalty and license agreement

We are reliant on direct and indirect sales of the Primi and Pluri lines for humans and the All-in-One animal products for revenues, none of which has produced any significant revenue yet. We have very limited experience in marketing and have yet to develop reliable sales expectations and forecasting.

Market and Marketing

We market our science-based, quality nutraceuticals to a broad base of the population in the U.S., and are exploring marketing prospects in Asia, Australasia, the Middle East, and Europe. The Company’s current target markets also include equine and canine companion animals and equine competitors in the U.S., Australasia and the Middle East.

During June 2021, we commenced use of social media professionals and existing connections to create awareness about our human products’ benefits. The initial results were not satisfactory and a recast, animal product-specific program that followed later in 2021, similarly failed. We are developing affiliate marketing opportunities and recognized that a broader campaign using traditional advertising along with social media and more contemporary marketing tools is necessary. We re-launched our social media and internet-based marketing activities in 2Q 2022, commencing with a complete website redesign, and are seeking a new social media manager to organize our efforts

16
Table of Contents

We are pursuing scientific surveys and other testing to demonstrate the usefulness of our products. While we do not anticipate developing testing protocols suitable for FDA approvals, we expect anecdotal and testimonial reports that will be useful in our marketing efforts. The Company is currently participating in a survey involving the use of PluriPain® by patients suffering from Gadolinium Deposition Disease (“GDD”), and a combination of products for COVID Long Hauler patients. In the GDD survey, 60% of a small subject sample reported significant relief. The COVID Long Hauler survey has limited participation to date and no results. We expect to continue these explorations in 3Q and 4Q 2022.

Although we believe our newly formulated MindnMemory™ product is a substantial improvement over PrimiLive®™, our other products have not substantially changed: We offer premium nutraceutical preparations containing the best quality all-natural botanical and algal ingredients. We will continue to emphasize the unique qualities, use and function of our nutraceuticals. We intend to create market share in our target demographic by (i) emphasizing the benefits of our proprietary algal-based, all-natural, stimulant-free, non-GMO ingredients that combine with proven Traditional Chinese Medicine and Ayurvedic botanicals into science-based formulations, (ii) investigating additional products in response to market demand and testing, and (iii) utilizing our marketing operation to act as its sales and distribution arm to seek additional channels for sales coverage.

As noted above, we entered into licensing agreements for the PrimiLive® and PrimiSleep™ products during 2021, and developed our reformulated MindnMemory™ during 2022. While these products are all-natural botanical formulations, as our other nutraceutical products, they represent a departure from our existing product lines because they are targeted to specific markets: MindnMemory™ is a nootropic, intended to improve concentration and mental acuity; our initial marketing efforts are oriented toward Seniors and e-gamers. PrimiSleep™ is intended for use as an aid to relaxation, with an emphasis on improving the quality of sleep. We believe these products can be used in a complementary manner, to maintain on-task endurance and then to unwind and recover from such activities.

In addition, we are investigating the use of a formulation of PluriPain® targeted toward the symptoms of pre-menstrual syndrome and menstrual pain. Anecdotal and testimonial reports have long noted that users obtain relief from these symptoms with use of the PluriPain® product, and we have made adjustments and additions to the formulation to target these symptoms. Early reports are promising, and we expect marketing efforts to emphasize the usefulness of our product to alleviate PMS-related symptoms.

We are also exploring the combination of PluriPain®, PrimiLung™ and PrimiSleep™ for COVID Long Haulers in the on-going Survey conducted by Regina Sutton, M.D. These. specific formulations address some of the most troubling symptoms of long-term COVID sufferers, including brain fog, pain and sleep problems.

The Company believes that products using our oxygenated water technology will be useful and commercially viable. Water products manufactured using the technology demonstrate significantly high dissolved O2 levels that persist over an extended period, exceeding levels and persistence in other commercial products. Users of oxygenated water produced with our technology report enhanced physical endurance, stamina and performance. We are currently arranging a pilot run of the oxygenated water product and are exploring usage in topical and other applications.

With regard to animal products, the Company’s Livestock Impact Division entered into exclusive Marketing and Licensing Agreement with the owners of its Equine All-in-One™ products. The President of the Division is Bruce Colclasure, a National Cutting Horse Association champion who owns and operates the Flying C Bar Ranch and is the breeder and trainer of over 80 NCHA champion cutting horses. Mr. Colclasure uses and endorses our Equine All-in-One™ and booster products and provides valuable feedback and testimonials regarding its function. In addition, a high-performance formulation of our All-in-One product is used by quarter horse trainers at facilities in Oklahoma and New Mexico, with exceptional results. We expect to use these results in our marketing efforts in 2022 and to expand our outreach program for performance horse trainers.

17
Table of Contents

In light of the failures of our social media campaigns, in 2021, we commenced a marketing affiliate outreach program, directly contacting the principals of horse clubs and associations, offering discounts, samples and other inducements, seeking to develop “product champion” and “maven” relationships. We contacted principals in organizations with thousands of members and many more thousands of horses. We distributed samples and marketing materials to approximately 40 principals and influencers in regional and breed-specific equine associations and anticipate feedback from these marketing initiatives in the fourth quarter.

Based in part on these initial returns, effective March 3, 2022, we commenced print and internet ad campaigns in two equine sports magazines, Quarterhorse News and Barrel Horse News; print ads began in April 2022, and has continued in 2022.

Manufacturing

All of the Company’s nutraceutical products are considered dietary supplements or natural foods, and we carefully avoid making health, drug or disease cure claims that could trigger regulatory compliance issues and affect our ability to market BioAdaptives products. Our active ingredients are all plant- or algal-based and sourced worldwide from reputable suppliers who employ stringent compliance and sustainable agriculture practices or operate NSF-certified (or equivalent) facilities.

We contract exclusively with manufacturers that utilize pharmaceutical grade facilities to assemble and package our products, all of which is subject to our inspection and approval. Fulfillment of retail internet and direct-to-reseller orders are conducted from our warehouse facilities. BioAdaptives actively investigates new products, techniques and novel applications of existing products or technology in our research. The Company’s research work has centered on investigations of all-natural supplement formulations that activate primitive cells, including stem cells and their derivatives, and natural ingredients that encourage stem cell proliferation.

We are exploring the means to bring one or more specialized water products to market. Our technology has been tested in a large scale plant to produce bottled water, proving the process is viable and the machinery functional. The costs of using our technology is modest – pennies per bottle – but we recognize there are numerous better-capitalized manufacturers, many of whom also have excellent branding and market distribution. We contracted with a large Las Vegas bottling company to manufacture a pilot run but technical difficulties have delayed production. We intend to put promotional products in the hands of athletes and sports figures, in furtherance of a marketing program based on user testimonials and possible endorsements. We will also consider licensing opportunities with competitors or other manufacturers.

As noted above, it is our intention to operate primarily as a marketing company, developing consumer markets for nutraceutical products and medical devices that we license or market for others.

Employees

The Company currently has 3 full-time non-executive employees and 4 part-time employees. We retain hourly labor on an as-needed basis and professional consultants to operate our business. Management of the Company expects to continue use of outside consultants, attorneys, and accountants, as necessary, so long as it is seeking and evaluating business opportunities. The need for additional employees, and their availability, will be addressed in connection with the decision whether or not to acquire or participate in specific business opportunities.

2. LIQUITITY AND CAPITAL RESOURCES:

Liquidity -- Financial Performance – Three Months Ended June 30, 2022 and 2021

We had a net loss of $223,837 for the three-month period ended June 30, 2022, which was $85,409 less than the net loss of $309,246 for the three-month period ended June 30, 2021. The change in our results over the two periods is primarily from a decrease in operating and other expenses, specifically, stock-based compensation.

18
Table of Contents

The following table summarizes key items of comparison and their related increase (decrease) for the three-month periods ended June 30, 2022 and 2021:

		****		****
Revenue	4,322		6,065		(1,743	)
Cost of Sales	2,169		2,713		(544	)
Operation Expenses	23,821		25,625		(1804	)
Other income (expenses)	(80,540	)	(237,644	)	157,104
Net Income (loss)	(223,837	)	(309,246	)	85,404

Revenue

Our revenues have been derived entirely from product sales.

Cost of Sales

Our cost of sales is primarily derived from contract manufacturing expenses and shipping and handling expenses related to customer fulfillment. We also expense marketing expenses, which includes the cost of samples or products provided for promotional purposes and website content development. We have contracted for consulting services relating to website and product label redesign and another social media outreach campaign, and we expect expenses to accrue for such services in 3Q 2022, and beyond.

Operation Expenses

Our general, administrative and professional fees are largely attributable to office, rent, advertising, consultants and transfer agent, legal, accounting and audit fees related to our reporting requirements as a public company as well as stock-based compensation for officers, directors and consultants.

Other Income (Expense)

The Company recorded interest expense of $75,367 and $15,833 for the three months ended June 30, 2022, and 2021.

Net Loss

As a result of our operating expenses the Company reported a net loss of $233,837 and $309,246 for the three months ended June 30, 2022 and 2021.

Capital Resources – Balance Sheet and Cash Flows

Our balance sheet as of June 30, 2022 reflects current assets of $61,227, including cash in the amount of $49,517 and working capital deficiency in the amount of $1,494,946. We currently meet cash requirements by infusions of cash from issuance of notes to finance partners and advances from shareholders. Most of these notes have conversion features that require accounting for derivative liabilities. We are hopeful that our pending Reg. A+ offering will reduce our financing costs but can provide no assurances as to whether our offering will be successful. To-date, our market share prices has remained below the offering price for our stock in the Reg A+ offering and until that changes it is unlikely the offering will generate funds.

19
Table of Contents

Working Capital (Deficiency)

	June 30		June 30
	2022		2021		Change
Current Assets		62,227		80.971		11,594
Current Liabilities		1,564,323		1,406,922		(95,174	)
Working Capital (Deficiency)		1,502,096		1,325,951		(176,145	)

Cash Flows

	Six Months Ended<br><br>June 30
	2021			2021			Change
Cash provided by (used in) Operating Activities Cash provided in Investing Activities<br><br>Cash provided by (used in) Financing Activities		(133,147	)		(90,074	)		(43,073	)
Net Increase (Decrease) In Cash During Period		99,728			155,000			(55,272	)

Net cash used by operating activities during the six months ended June 30, 2022 was $133,147, a decrease of $43,073 from net cash used in operating activities during the six months ended June 30, 2021.

Cash Flows from Financing Activities

Net cash provided by financing activities during the six months ended June 30, 2022 was $99,728, a decrease of $55,272 from net cash provided in financing activities during the six months ended June 30, 2021.

As of June 30, 2022, we have insufficient cash to operate our business at the current level for the next twelve months and insufficient cash to achieve our business goals. The success of our business plan beyond the next 12 months is contingent upon us obtaining additional financing. We intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund our capital expenditures, working capital, or other cash requirements. We do not have any formal commitments or arrangements for the sales of stock or the advancement or loan of funds at this time. There can be no assurance that such additional financing will be available to us on acceptable terms, or at all.

Critical Accounting Estimates -- Going Concern

We are required to provide qualitative and quantitative information necessary to understand any critical accounting estimations, including uncertainties associated with such estimates. Our critical accounting estimates, as well as the financial statements contained in this report, are all reliant on the assumption that we will continue as a going concern, which contemplates our ability to generate sufficient cash flows from operations and financing activities necessary to continue in business by employing our assets and satisfying our liabilities in the normal course of business.

On June 30, 2022, we had $49,517 of cash on-hand and an accumulated deficit of $7,247,077, and as noted throughout this report and our financial statements and notes thereto, our independent auditors expressed their substantial doubt as to our ability to continue as a going concern as of December 31, 2021. We anticipate incurring significant losses in the future. We do not have an established source of revenue sufficient to cover our operating costs. Our ability to continue as a going concern is dependent upon our ability to successfully compete, operate profitably and/or raise additional capital through other means. If we are unable to reverse our losses, we will have to discontinue operations.

20
Table of Contents

Because our business plan relies on marketing products we license from others, our capital requirements are generally limited to general operations and administration, including the costs of continuing as a public company, and our variable costs scale up or down based on our actual sales. We believe that increasing our marketing expenses will be critical to establishing sales sufficient to cover our expenses and, if possible, generate a profit. We anticipate using our existing financing operations to do so, which will almost certainly require either the issuance of equity or increases in existing levels of debt or, most likely, both.

Management's plans include the raising of capital through the equity markets to fund future operations, seeking additional acquisitions, and generating of revenue through our business. However, even if we do raise

sufficient capital to support our operating expenses and generate adequate revenues, there can be no assurances that the revenue will be sufficient to enable us to develop business to a level where we will generate profits and positive cash flows from operations. These matters raise substantial doubt about our ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, and capital expenditures or capital resources that are material to stockholders.

Critical Accounting Policies

Our financial statements are based on the application of accounting principles generally accepted in the United States ("US GAAP"). US GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenue, and expense amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to US GAAP and are consistently and conservatively a that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.

Recent Accounting Pronouncements

The Company has evaluated recent pronouncements through Accounting Standards Updates ("ASU") and believes that none of them will have a material impact on the Company's financial position, results of operations or cash flows.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company,” we are not required to provide the information required by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15 under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this quarterly report, June 30, 2022. This evaluation was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our company's reports filed under the Securities Exchange Act of 1934 is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Based upon that evaluation, including our Chief Executive Officer and Chief Financial Officer, we have concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this report due to a material weakness in our internal control over financial reporting, which is described below.

21
Table of Contents

Management's Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934). Management has assessed the effectiveness of our internal control over financial reporting as of June 30, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. As a result of this assessment, management concluded that, as of June 30, 2022, our internal control over financial reporting was not effective. Our management identified the following material weaknesses in our internal control over financial reporting, which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment. and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

We plan to take steps to enhance and improve the design of our internal control over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we hope to implement the following changes during our fiscal year ending December 31, 2022: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out in (i) and (ii) are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

To a certain extent, the size of our operation provides inherent checks and balances relative to internal controls: Because of our limited staff size and the integration of our executives and directors in operations, the prospect for significant internal control failures resulting in unreliable financial statements or worse is remote. Regardless, we recognize the importance of multiple layers of reporting and controls and are working toward improving our capabilities.

Changes in Internal Control over Financial Reporting

There was no change in the Company's internal control over financial reporting that occurred during the Company's most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

22
Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

At this time, we know of no pending legal proceedings of any manner to which we are a party, either individually or in the aggregate. We are from time-to-time, during the normal course of our business operations, subject to various litigation claims and legal disputes. There are no such claims or disputes pending at this time and we have not been notified of any possible claims or disputes.

Item 1A. Risk Factors

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Covid-19 Pandemic Impact and Risk

At this time, it is not possible to fully assess the impact of the COVID-19 pandemic on the Company’s operations and capital requirements. While we have noted that economic headwinds have eased generally, our business is impacted by numerous other influences. Business activities from 1Q 2020 onward were substantially curtailed: Our key executives were unable to travel, which impacted our financing operations. Consumer demand was generally down in our target markets, even though we offer products that are generally considered to promote health. We delayed much of our marketing activity due to travel, funding and perceived demand issues.

We re-launched our marketing efforts during 1Q 2022, but these have been slow to gain traction. The other factors impeding growth of our business have significantly changed: travel restrictions have eased and our finance partners have cash for investments or debt issuance. Consumer demand for our products, however, has not increased significantly. We believe this has more to do with poor reception to our marketing initiatives and the fact that we operate in a crowded market space, with several better known and capitalized competitors.

23
Table of Contents

The CDC reports that US children and adults should remain vigilant to new mutations of the COVID-19 virus, and that the pandemic will likely continue to impact groups that comprise our intended consumers. Should the pandemic reignite, the Company may be faced with the same headwinds we saw during 2021, which may adversely affect the Company’s ability to (i) retain employees and consultants; (ii) obtain additional financing on terms acceptable to the Company, if at all; (iii) delay regulatory submissions and approvals, if required; (iv) delay, limit or preclude the Company from securing manufacturing sites, partnerships or marketing agreements; (v) delay, limit or preclude the Company from achieving technology or product development goals, milestones, or objectives; and (vi) preclude or delay entry into joint venture or partnership arrangements. The occurrence of any one or more of such events may affect the Company’s ability to execute on its business plan

During 2Q 2022, the Company commenced sponsorship of a COVID Long Hauler Survey, providing funding for scientific uses and samples of our pain, pulmonary and sleep products to participants. While we do not (and cannot) make any manner of drug-type or treatment claims regarding disease, the Company has received anecdotal reports that certain combinations of our products provide relief from certain long-term COVID symptoms, including brain fog, persistent pain, and sleep disruptions. Although we are careful to not make any COVID-related claims in our marketing materials, we intend to pursue this survey for general scientific purposes to determine additional uses for our products

The Company’s priority and commitment is to the health and security of its team members, their families and its partners through this unprecedented pandemic.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

We issued equity securities during this reporting period to satisfy convertible notes to our finance partner, Power-Up Lending Group, Ltd.; the structure and terms of these obligations is the same as made in previous periods. The table below sets out these issuances during the period from April 1, 2022 to and including June 30, 2022.

POWER UP LENDING GROUP LTD	2,909,091	04/01/2022
POWER UP LENDING GROUP LTD	2,906,250	04/07/2022
POWER UP LENDING GROUP LTD	3,201,563	04/11/2022
1800 DIAGONAL LENDING, LLC	3,360,000	06/21/2022
1800 DIAGONAL LENDING, LLC	3,360,000	06/23/2022
1800 DIAGONAL LENDING, LLC	3,360,000	06/27/2022

Total: 19,096,904

Additional notes will come due during the periods ending August 30 and December 31, 2022, and we anticipate issuance of common shares upon Power-Up’s or 1800 Diagonal Lending’s demand.

The Company modified its Employment Agreements with Charles Townsend, Chief Operating Officer, Officer and Secretary/Treasurer, and Robert W. Ellis, President, and entered into a new Employment Agreement with Dr. Edward E. Jacobs, MD, or Chief Executive Officer and Chairman, during 1Q 2022. We terminated requirements to deliver Restricted Stock Units and initiated compensation by warrants. These agreements provide for payment of a number of warrants to purchase shares equal to two-times the cash value of accrued salary, to be issued based on OTC Markets closing price as of June 30 and December 31. These modifications were reported in a Form 8-K previously filed by the Company. On June 30, 2022, our closing share price was $.0033, and we will issue two-year warrants for the purchase of 15,151,152 shares at this price to each of these executives.

24
Table of Contents

Item 3. Defaults Upon Senior Securities

The Company has no senior securities, but has outstanding instruments previously characterized as unsecured convertible debentures. These instruments are not senior to any other Company obligation. The Company arranged extension and forbearance agreements with the holders of the 12% Debentures, which were issued in 2018 and were due at various times in 2020. Our agreement called for the extension of these obligations on the same terms until December 31, 2021, in exchange for current interest payments and delivery of 280,000 shares of its common stock (total). We are currently in default on these obligations but are working on an alternative resolution.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Nothing to add.

Item 6. Exhibits

31.1	Section 302 Certification by the Principal Executive Officer
31.2	Section 302 Certification by the Principal Financial Officer
32.1	Section 906 Certification by the Principal Executive Officer
32.2	Section 906 Certification by the Principal Financial Officer
25
---
Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BioAdaptives Inc.
	(Registrant)
Dated: August 12 2022
		/s/ Dr. Edward E. Jacobs, M.D.
		Dr. Edward E. Jacobs, M.D.<br><br>Chief Executive Officer
		/s/ Robert W. Ellis
		Robert W. Ellis<br><br>Principal Financial Officer
26
---

bdpt_ex311.htm

EXHIBIT 31.1

BIOADAPTIVES INC.

OFFICER'S CERTIFICATE PURSUANT TO SECTION 302

I, Edward E. Jacobs, Jr, certify that:

1.	I have reviewed this Form 10-Q of BioAdaptives Inc.
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.
4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.	Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared.
b.	Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
c.	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: August 12, 2022		/s/Edward E. Jacobs, Jr

| | By: | Edward E. Jacobs, Jr Chief Executive Officer (Principal Executive Officer) |

bdpt_ex312.htm

EXHIBIT 31.2

BIOADAPTIVES INC.

OFFICER'S CERTIFICATE PURSUANT TO SECTION 302

I, Robert W. Ellis, certify that:

1.	I have reviewed this Form 10-Q of BioAdaptives Inc.
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.
4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.	Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared.
b.	Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
c.	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: August 12, 2022		/s/Robert W. Ellis

| | By: | Robert W. Ellis |

| | | Principal Financial Officer |

bdpt_ex321.htm

EXHIBIT 32.1

BIOADAPTIVES INC.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BioAdaptives Inc. (the Registrant) on Form 10-Q for the period ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Edward E. Jacobs, Jr, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to Edward E. Jacobs, Jr and will be retained by BioAdaptives Inc. and furnished to the Securities and Exchange Commission for or its staff upon request.

Dated: August 12,2022	/s/ Edward E. Jacobs, Jr

| | Edward E. Jacobs, Jr |

| | Chief Executive Officer (Principal Executive Officer) |

bdpt_ex322.htm

EXHIBIT 32.2

BIOADAPTIVES INC.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BioAdaptives Inc. (the Registrant) on Form 10-Q for the period ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Robert W.Ellis, Principal Accounting Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to Robert W. Ellis and will be retained by BioAdaptives Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

Dated: August 12, 2022	/s/ Robert W. Ellis

| | Robert W. Ellis |

| | Principal Accounting Officer |

10-Q

Form 10-Q

(702) 659-8829

N/A

Table of Contents

1. DESCRIPTION OF BUSINESS AND HISTORY

COVID-19

2. SUMMARY OF SIGNIFICANT POLICIES

3. GOING CONCERN

4. MARKETABLE SECURITIES

5. LICENSE AND PATENT

6. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

7. CONVERTIBLE NOTES

8. DERIVATIVE LIABILITIES

9. STOCKHOLDERS’ EQUITY

10. RELATED PARTY TRANSACTIONS

12. SUBSEQUENT EVENTS

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Item 4. Controls and Procedures

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

Item 1A. Risk Factors

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Item 3. Defaults Upon Senior Securities

Item 4. Mine Safety Disclosures

Item 5. Other Information

Item 6. Exhibits

SIGNATURES